Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule featuring a thiourea backbone linked to two substituted pyridine rings—one with fluoro and ethoxy groups, the other with a chloro group. It is classified as an experimental molecule and has not been approved for clinical use. The compound has been studied structurally (PDB ligand code: FTC), but there are no published indications, clinical trials, or known therapeutic uses. Some structural studies have associated it with research on HIV proteins, suggesting possible utility as an antiviral probe or inhibitor in preclinical settings; however, no mechanism of action or biological target has been definitively established[1][6][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[[3-fluoro-4-ethoxy-pyrid-2-yl]ethyl]-N'-[5-chloro-pyridyl]-thiourea.